Industry Verticals »

All Categories

Insights »

About TMR »

Active Pharmaceutical Ingredients (API) Market Report, 2021-2031

Active Pharmaceutical Ingredients (API) Market (Manufacturer Type: In House Manufacturing and Contract Manufacturing; Drug Type: Branded or Innovative Prescription Drugs, Generic Prescription Drugs, and Over-the-counter [OTC] Drugs; API Type: Synthetic, Biological, and Plant Extracts; Application: Anti-infective, Cardiovascular, Neurological, Metabolic Disorder, Respiratory, Oncology, and Others; and End User: Pharmaceutical & Biotechnological Industry, CROs, CMOs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

International Regulation for APIs Helps Improve Drug Standards

Active pharmaceutical ingredient (API) refers to the active component in a drug. In simple terms, API is part of any drug that produces the intended effects. Drugs are usually formed from several components. The API acts as the primary ingredient. Other ingredients are commonly called excipients, and these elements are required to be biologically innoxious, often forming a changeable fraction of the drug product. The procedure for optimizing and compositing this mixture of ingredients used in medicine is referred to as formulation. Some drugs have multiple active APIs to treat various symptoms or act in complex ways. Most of the production of APIs has been carried out by local pharmaceutical companies. However, in previous years, many businesses have opted to transfer manufacturing overseas to cut costs. The increasing demand for pharmaceutical drugs is expected to expand the global active pharmaceutical ingredients (API) market during the forecast period.

Defectively produced and contaminated active ingredients have been associated with adverse health outcomes, extending to death, in several incidents over the past decades. Therefore, most nations across the globe are now regulating active ingredients. Regulating active ingredients can help improve the quality and safety of drugs for consumers, can extend the pharmaceutical drug supply system across the globe, and will bring the active pharmaceutical ingredients market into line with its international regulatory partners. Moreover, producers use specific measures to determine the strength of API in each drug. The measure can vary extensively from one brand to another. Every brand might use different test techniques that can result in various strengths. Nevertheless, the growing incidents of chronic diseases are expected to increase the global demand for the active pharmaceutical ingredient market.

Supply Chain Restrictions on China Hampered Global API Production

During the COVID-19 crisis, pharmaceutical companies are fighting with the prompt hurdles arising from the disruption in supply chains and the mandate to change business functioning. It was anticipated that if the COVID-19 pandemic continues for a medium/long span of time, it may impact the supply of active material and ingredients from the Asia Pacific with all the import and export of pharmaceuticals globally. The global reliance on China for APIs in various biologics and generic drugs was halted with the operations of manufacturing as directed by the government. The closure of manufacturing in India and China led to a decline in the global supply of drugs when the demand was at an all-time high. This has led to several countries rolling out programs for domestic API production. Moreover, nations across the EU have reassessed their healthcare standards for tackling the virus and securing a constant inflow of API production.

As the end of this crisis approaches, many manufacturers of active pharmaceutical ingredients are returning their focus to their pre-COVID projects, especially in the essential drugs segment.  Leading pharmaceutical businesses are adopting new business models and offering solutions based on key performance indicators by nation. Healthcare expenses of society and the current COVID-19 crisis have driven pharmaceutical producers to realign their standards to provide to a large patient pool. However, the impact of coronavirus is anticipated to considerably decrease organizational income and capital expenditures, as the shock solidified various organizations. This is most likely to result in increased investment from API manufacturers for the production, marketing, and promotion of their products. Nevertheless, with the rapid production and distribution of COVID-19 vaccines, global trade is set to reduce its limits for the global active pharmaceutical ingredient (API) market.

Synthetic API Likely to Witness Higher Demand

An API process is linked to a series of operations that result in the development of an active pharmaceutical ingredient. Major procedures or steps in the API process may include multi-step drug synthesis and fermentation, purification, crystallization, drying, milling, packing, labeling, and testing. Some drugs treated similarly to an API may be bulk-finished products. Moreover, active pharmaceutical ingredients in pediatric formulations have drawn significant attention from regulatory agencies across the world, due to safety concerns. In drug pipelines, small molecule drugs are trending in popularity presently. Small molecule drugs have the maximum number of regulatory approval, and the growing trend is anticipated to continue in the upcoming future. This is likely to benefit the active pharmaceutical ingredients (API) market.

The market share of synthetic API processes has surpassed the biological process. However, biological API production is growing faster than the synthetic process during the projected timeline. In addition, factors such as an increase in aging populations in most of the western world and the prevalence of chronic disease are contributing to the growth of the market for active pharmaceutical ingredients (API). Bio-production is growing more widespread as a way to manufacture safer and more efficient drugs. Innovative and inventive methods for curing cancer, cystic fibrosis, asthma, blindness, and heart disease are increasing the demand for biological drugs. Bio-pharmaceuticals operate with the body to defend itself, while synthetic drugs often simply shield the consequences of a disease. Furthermore, in 2020, the cardiovascular segment accounted for a major share of the global active pharmaceutical ingredients market.

Hypertension and cardiovascular diseases are common diseases and account for significant medical disability and deaths worldwide. The growing demand for pharmaceutical products to treat the increasing number of patients is proving propitious for the global market for active pharmaceutical ingredients (API) during the forecast period.

Due to all the above-mentioned factors, the global active pharmaceutical ingredients (API) market is expected to reach a market value of US$ 331.3 Bn in 2031, expanding at a CAGR of 6.4% from 2021 to 2031.

Analysts’ Viewpoint

Rise in prevalence of diseases & disorders and growth in government & organizational investments to develop APIs are major contributors to the expansion of the global active pharmaceutical ingredients (API) market. In addition, advancements in research & technology on biological processes and small molecule APIs are expected to prove beneficial for the increasing market demand. Moreover, the demand for higher quality, cost-effective drugs across the supply chain is reshaping the active pharmaceutical ingredients market. The focus of manufacturers on innovative and decisive measures is anticipating new strategic plans post COVID-19 era. However, the global active pharmaceutical ingredient (API) market is projected to recover from the pandemic losses and shocks over the next few years.

Active Pharmaceutical Ingredients (API) Industry: Overview

  • An active pharmaceutical ingredient (API) is any substance or mixture of substances used in the finished pharmaceutical product (FPP) that is intended to provide pharmacological action or to otherwise have a direct impact in the diagnosis, remedy, mitigation, therapy, or prevention of disease, or to have a direct effect in repairing, correcting, or altering physiological functions in humans
  • The global active pharmaceutical ingredients (API) market has experienced significant growth in the last decade, due to an increase in the incidence of chronic diseases
  • Increase in Abbreviated New Drug Applications (ANDA) drives demand for active pharmaceutical ingredients (API). In order to market a generic drug, a company needs to file an Abbreviated New Drug Application (ANDA). An ANDA approval implies that the generic drug is comparable to the original drug in terms of dosage form, strength, route of administration, quality, performance characteristics, and intended use.
  • However, companies cannot manufacture a drug unless the patent of a drug expires. Hence, as billion-dollar drugs lose patents, other drug manufacturers grab the opportunity to manufacture low-cost generics and file for ANDA to the U.S. FDA.
  • The pharmaceutical industry has suffered significantly due to the patent expiry of blockbuster drugs in the past few years. Demand for low-cost substitutes is high in low- and middle-income countries in Asia Pacific, Africa, and Latin America. This increases the number of API manufacturers, as pharmaceutical drug manufacturers did not have enough in-house capacity to meet the demand.
  • Currently, the majority of API manufacturers are concentrated in Asia Pacific, primarily India, China, and Taiwan. Teva Active Pharmaceutical Ingredients (TAPI), Aurobindo, and Sun Pharma are the leading API manufacturers in the region.
  • An increase in the incidence of chronic diseases drives the global active pharmaceutical ingredients (API) market. According to the International Diabetes Federation, in 2019, 463 million people across the world were diagnosed with diabetes. Moreover, the number of new cancer cases per year is expected to increase to 23.6 million by 2030. Apart from cancer, a number of other diseases have shown a rise in prevalence rates. The rise in prevalence of cancer, cardiovascular diseases, and diabetes; the surge in sedentary lifestyles; and the increase in the geriatric population are the key drivers of the global market.
  • Lung cancer is the leading cause of cancer deaths in Asia Pacific. China alone accounts for over 50% of all cancer cases in the region. Changes in lifestyle and socio-cultural factors are the leading causes of cervical cancer. The major countries affected by breast cancer in the Asia Pacific are India, Thailand, and China.
  • Small molecule drugs account for a major share of the current drug pipeline. Despite new biologic entities entering the market, small molecules are experiencing a surge in usage in the clinical pipeline. The maximum number of FDA approvals in the last decade has been for small-molecule drugs, and the trend is likely to continue during the forecast period.

Market Segmentation: Active Pharmaceutical Ingredients (API) Business

  • In terms of manufacturer type, the global active pharmaceutical ingredients (API) industry have been classified into in-house manufacturing and contract manufacturing. The in-house manufacturing segment is anticipated to dominate the global active pharmaceutical ingredients (API) market during the forecast period.
  • Based on drug type, the global active pharmaceutical ingredients market has been categorized into branded or innovative prescription drugs, generic prescription drugs, and over-the-counter (OTC) drugs. The branded or innovative prescription drugs segment dominated the global active pharmaceutical ingredient (API) market in terms of revenue in 2020.
  • In terms of API type, the global API market has been divided into synthetic, biological, and plant extracts. The synthetic segment dominated the global active pharmaceutical ingredients (API) market in terms of revenue in 2020.
  • Based on application, the global active pharmaceutical ingredients (API) market has been segregated into anti-infective, cardiovascular, neurological, metabolic disorders, respiratory, oncology, and others. The cardiovascular segment dominated the global market in terms of revenue in 2020.
  • In terms of end users, the global market for active pharmaceutical ingredients (API) has been split into the pharmaceutical & biotechnological industry, CROs, CMOs, and others. The pharmaceutical & biotechnological industry segment dominated the global active pharmaceutical ingredients market in terms of revenue in 2020.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Bn) for each of these segments from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Active Pharmaceutical Ingredient (API) Market

  • In terms of region, the global active pharmaceutical ingredients (API) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and expected market revenue (US$ Bn) of these regional markets and their major countries have been provided in the report from 2017 to 2031, with their CAGRs from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights into the global active pharmaceutical ingredient (API) market, which would help new companies willing to enter the market and existing companies to increase market shares in the decision-making process

Major Players

  • The active pharmaceutical ingredients (API) market report concludes with the company profiles section, which includes key information about major players in the global market
  • Leading players analyzed in the active pharmaceutical ingredients (API) industry report include
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer, Inc.
    • Novartis AG
    • Mylan N.V.
    • Lonza
    • WuXi AppTec Co., Ltd.
    • Piramal Pharma Solutions
    • Hisun USA, Inc.
    • Ipca Laboratories Ltd.
    • AbbVie, Inc.
    • Alembic Pharmaceuticals Limited
    • BASF SE
    • Biocon Ltd.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Cambrex Corporation
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
  • Each of these players has been profiled in the active pharmaceutical ingredients market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Active Pharmaceutical Ingredients (API) Market – Segmentation

TMR’s study on the global active pharmaceutical ingredient (API) market includes information divided into five segments: manufacturer type, drug type, API type, application, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global active pharmaceutical ingredients market are discussed in detail.

Manufacturer Type
  • In House Manufacturing
  • Contract Manufacturing
Drug Type
  • Branded or Innovative Prescription Drugs
  • Generic Prescription Drugs
  • Over-the-counter (OTC) Drugs
API Type
  • Synthetic
  • Biological
  • Plant Extracts
Application
  • Anti-infective
  • Cardiovascular
  • Neurological
  • Metabolic Disorder
  • Respiratory
  • Oncology
  • Others
End User
  • Pharmaceutical & Biotechnological Industry
  • CROs
  • CMOs
  • Others
Region
  • North America
  • Europe
  • Asia pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of active pharmaceutical ingredients (API) market?

The global active pharmaceutical ingredients market was worth US$ 168 Bn and is projected to reach a value of US$ 331.3 Bn by the end of 2031

What is the anticipated CAGR of the active pharmaceutical ingredient market in the forecast period?

The active pharmaceutical ingredient (API) market is anticipated to grow at a CAGR of 6.4% during the forecast period

Which region is expected to project the highest market share in the global active pharmaceutical ingredients (API) industry?

North America accounted for a major share of the global active pharmaceutical ingredient (API) market

What are the key driving factors for the growth of the active pharmaceutical ingredients market?

The increase in the incidence of chronic diseases drives the global API market

Who are the key players in the global active pharmaceutical ingredients (API) industry?

Key players in the global active pharmaceutical ingredient (API) market include Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer, Inc., Novartis AG, Mylan N.V., Lonza, WuXi AppTec Co., Ltd., Piramal Pharma Solutions, Hisun USA, Inc., Ipca Laboratories Ltd., AbbVie, Inc., Alembic Pharmaceuticals Limited, BASF SE, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cambrex Corporation, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, and

    1. Preface

        1.1. Report Scope and Market Segmentation

        1.2. Research Highlights

    2. Assumptions and Research Methodology

        2.1. Assumptions and Acronyms Used

        2.2. Research Methodology

    3. Executive Summary

    4. Market Overview

        4.1. Introduction

        4.2. Key Industry Developments

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunity

        4.4. Global Active Pharmaceutical Ingredients (API) Market Forecast

    5. Key insights

        5.1. Value Chain Analysis

        5.2. Upcoming Patent Expiry of Major Drugs

        5.3. Clinical Trial Analysis

        5.4. COVID-19 Pandemic Impact on Active Pharmaceutical Ingredients (API)s Industry

        5.5. Key Industry Development

    6. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Manufacturer Type

        6.1. Introduction

        6.2. Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type

        6.3. Global Active Pharmaceutical Ingredients (API) Market Forecast, by Manufacturer Type

            6.3.1. In House Manufacturing

            6.3.2. Contract Manufacturing

        6.4. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Manufacturer Type

        6.5. Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type

    7. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        7.1. Introduction

        7.2. Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type

        7.3. Global Active Pharmaceutical Ingredients (API) Market Forecast, by Drug Type

            7.3.1. Branded or Innovative Prescription Drugs

            7.3.2. Generic Prescription Drugs

            7.3.3. Over-the-counter (OTC) Drugs

        7.4. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        7.5. Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type

    8. Global Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        8.1. Introduction

        8.2. Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type

        8.3. Global Active Pharmaceutical Ingredients (API) Market Forecast, by API Type

            8.3.1. Synthetic

            8.3.2. Biological

            8.3.3. Plant Extracts

        8.4. Global Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        8.5. Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type

    9. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        9.1. Introduction

        9.2. Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application

        9.3. Global Active Pharmaceutical Ingredients (API) Market Forecast, by Application

            9.3.1. Anti-infective

            9.3.2. Cardiovascular

            9.3.3. Neurological

            9.3.4. Metabolic Disorder

            9.3.5. Respiratory

            9.3.6. Oncology

            9.3.7. Others

        9.4. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        9.5. Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application

    10. Global Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        10.1. Introduction

        10.2. Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user

        10.3. Global Active Pharmaceutical Ingredients (API) Market Forecast, by End-user

            10.3.1. Pharmaceutical & Biotechnological Industry

            10.3.2. CROs

            10.3.3. CMOs

            10.3.4. Others

        10.4. Global Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        10.5. Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user

    11. Global Active Pharmaceutical Ingredients (API) Market Analysis, by Region

        11.1. Global Active Pharmaceutical Ingredients (API) Market Scenario, by Region/Country

        11.2. Global Active Pharmaceutical Ingredients (API) Market Value Share and Attractiveness Analysis, by Region

        11.3. Global Active Pharmaceutical Ingredients (API) Market Forecast, by Region

            11.3.1. North America

            11.3.2. Europe

            11.3.3. Asia Pacific

            11.3.4. Latin America

            11.3.5. Middle East & Africa

    12. North America Active Pharmaceutical Ingredients (API) Market Analysis

        12.1. North America Active Pharmaceutical Ingredients (API) Market Overview

        12.2. North America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, Manufacturer Type

        12.3. North America Active Pharmaceutical Ingredients (API) Forecast, by Manufacturer Type

            12.3.1. In House Manufacturing

            12.3.2. Contract Manufacturing

        12.4. North America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type

        12.5. North America Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        12.6. North America Active Pharmaceutical Ingredients (API) Market Forecast, by Drug Type

            12.6.1. Branded or Innovative Prescription Drugs

            12.6.2. Generic Prescription Drugs

            12.6.3. Over-the-counter (OTC) Drugs

        12.7. North America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type

        12.8. North America Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        12.9. North America Active Pharmaceutical Ingredients (API) Market Forecast, by API Type

            12.9.1. Synthetic

            12.9.2. Biological

            12.9.3. Plant Extracts

        12.10. North America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type

        12.11. North America Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        12.12. North America Active Pharmaceutical Ingredients (API) Market Forecast, by Application

            12.12.1. Anti-infective

            12.12.2. Cardiovascular

            12.12.3. Neurological

            12.12.4. Metabolic Disorder

            12.12.5. Respiratory

            12.12.6. Oncology

            12.12.7. Others

        12.13. North America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application

        12.14. North America Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        12.15. North America Active Pharmaceutical Ingredients (API) Market Forecast, by End-user

            12.15.1. Pharmaceutical & Biotechnological Industry

            12.15.2. CROs

            12.15.3. CMOs

            12.15.4. Others

        12.16. North America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user

        12.17. North America Active Pharmaceutical Ingredients (API) Market Value Share and Attractiveness Analysis, by Country

        12.18. North America Active Pharmaceutical Ingredients (API) Market Forecast, by Country

            12.18.1. U.S.

            12.18.2. Canada

    13. Europe Active Pharmaceutical Ingredients (API) Market Analysis

        13.1. Europe Active Pharmaceutical Ingredients (API) Market Overview

        13.2. Europe Active Pharmaceutical Ingredients (API) Market Value Share Analysis, Manufacturer Type

        13.3. Europe Active Pharmaceutical Ingredients (API) Forecast, by Manufacturer Type

            13.3.1. In House Manufacturing

            13.3.2. Contract Manufacturing

        13.4. Europe Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type

        13.5. Europe Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        13.6. Europe Active Pharmaceutical Ingredients (API) Market Forecast, by Drug Type

            13.6.1. Branded or Innovative Prescription Drugs

            13.6.2. Generic Prescription Drugs

            13.6.3. Over-the-counter (OTC) Drugs

        13.7. Europe Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type

        13.8. Europe Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        13.9. Europe Active Pharmaceutical Ingredients (API) Market Forecast, by API Type

            13.9.1. Synthetic

            13.9.2. Biological

            13.9.3. Plant Extracts

        13.10. Europe Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type

        13.11. Europe Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        13.12. Europe Active Pharmaceutical Ingredients (API) Market Forecast, by Application

            13.12.1. Anti-infective

            13.12.2. Cardiovascular

            13.12.3. Neurological

            13.12.4. Metabolic Disorder

            13.12.5. Respiratory

            13.12.6. Oncology

            13.12.7. Others

        13.13. Europe Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application

        13.14. Europe Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        13.15. Europe Active Pharmaceutical Ingredients (API) Market Forecast, by End-user

            13.15.1. Pharmaceutical & Biotechnological Industry

            13.15.2. CROs

            13.15.3. CMOs

            13.15.4. Others

        13.16. Europe Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user

        13.17. Europe Active Pharmaceutical Ingredients (API) Market Value Share and Attractiveness Analysis, by Country/Sub-region

        13.18. Europe Active Pharmaceutical Ingredients (API) Market Forecast, by Country/Sub-region

            13.18.1. Germany

            13.18.2. France

            13.18.3. U.K.

            13.18.4. Italy

            13.18.5. Spain

            13.18.6. Rest of Europe

    14. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis

        14.1. Asia Pacific Active Pharmaceutical Ingredients (API) Market Overview

        14.2. Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share Analysis, Manufacturer Type

        14.3. Asia Pacific Active Pharmaceutical Ingredients (API) Forecast, by Manufacturer Type

            14.3.1. In House Manufacturing

            14.3.2. Contract Manufacturing

        14.4. Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type

        14.5. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        14.6. Asia Pacific Active Pharmaceutical Ingredients (API) Market Forecast, by Drug Type

            14.6.1. Branded or Innovative Prescription Drugs

            14.6.2. Generic Prescription Drugs

            14.6.3. Over-the-counter (OTC) Drugs

        14.7. Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type

        14.8. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        14.9. Asia Pacific Active Pharmaceutical Ingredients (API) Market Forecast, by API Type

            14.9.1. Synthetic

            14.9.2. Biological

            14.9.3. Plant Extracts

        14.10. Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type

        14.11. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        14.12. Asia Pacific Active Pharmaceutical Ingredients (API) Market Forecast, by Application

            14.12.1. Anti-infective

            14.12.2. Cardiovascular

            14.12.3. Neurological

            14.12.4. Metabolic Disorder

            14.12.5. Respiratory

            14.12.6. Oncology

            14.12.7. Others

        14.13. Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application

        14.14. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        14.15. Asia Pacific Active Pharmaceutical Ingredients (API) Market Forecast, by End-user

            14.15.1. Pharmaceutical & Biotechnological Industry

            14.15.2. CROs

            14.15.3. CMOs

            14.15.4. Others

        14.16. Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user

        14.17. Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share and Attractiveness Analysis, by Country/Sub-region

        14.18. Asia Pacific Active Pharmaceutical Ingredients (API) Market Forecast, by Country/Sub-region

            14.18.1. Japan

            14.18.2. China

            14.18.3. India

            14.18.4. Australia & New Zealand

            14.18.5. Rest of Asia Pacific

    15. Latin America Active Pharmaceutical Ingredients (API) Market Analysis

        15.1. Latin America Active Pharmaceutical Ingredients (API) Market Overview

        15.2. Latin America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, Manufacturer Type

        15.3. Latin America Active Pharmaceutical Ingredients (API) Forecast, by Manufacturer Type

            15.3.1. In House Manufacturing

            15.3.2. Contract Manufacturing

        15.4. Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type

        15.5. Latin America Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        15.6. Latin America Active Pharmaceutical Ingredients (API) Market Forecast, by Drug Type

            15.6.1. Branded or Innovative Prescription Drugs

            15.6.2. Generic Prescription Drugs

            15.6.3. Over-the-counter (OTC) Drugs

        15.7. Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type

        15.8. Latin America Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        15.9. Latin America Active Pharmaceutical Ingredients (API) Market Forecast, by API Type

            15.9.1. Synthetic

            15.9.2. Biological

            15.9.3. Plant Extracts

        15.10. Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type

        15.11. Latin America Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        15.12. Latin America Active Pharmaceutical Ingredients (API) Market Forecast, by Application

            15.12.1. Anti-infective

            15.12.2. Cardiovascular

            15.12.3. Neurological

            15.12.4. Metabolic Disorder

            15.12.5. Respiratory

            15.12.6. Oncology

            15.12.7. Others

        15.13. Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application

        15.14. Latin America Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        15.15. Latin America Active Pharmaceutical Ingredients (API) Market Forecast, by End-user

            15.15.1. Pharmaceutical & Biotechnological Industry

            15.15.2. CROs

            15.15.3. CMOs

            15.15.4. Others

        15.16. Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user

        15.17. Latin America Active Pharmaceutical Ingredients (API) Market Value Share and Attractiveness Analysis, by Country/Sub-region

        15.18. Latin America Active Pharmaceutical Ingredients (API) Market Forecast, by Country/Sub-region

            15.18.1. Brazil

            15.18.2. Mexico

            15.18.3. Rest of Latin America

    16. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Analysis

        16.1. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Overview

        16.2. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Value Share Analysis, Manufacturer Type

        16.3. Middle East and Africa Active Pharmaceutical Ingredients (API) Forecast, by Manufacturer Type

            16.3.1. In House Manufacturing

            16.3.2. Contract Manufacturing

        16.4. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type

        16.5. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Analysis, by Drug Type

        16.6. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Forecast, by Drug Type

            16.6.1. Branded or Innovative Prescription Drugs

            16.6.2. Generic Prescription Drugs

            16.6.3. Over-the-counter (OTC) Drugs

        16.7. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type

        16.8. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Analysis, by API Type

        16.9. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Forecast, by API Type

            16.9.1. Synthetic

            16.9.2. Biological

            16.9.3. Plant Extracts

        16.10. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type

        16.11. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Analysis, by Application

        16.12. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Forecast, by Application

            16.12.1. Anti-infective

            16.12.2. Cardiovascular

            16.12.3. Neurological

            16.12.4. Metabolic Disorder

            16.12.5. Respiratory

            16.12.6. Oncology

            16.12.7. Others

        16.13. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application

        16.14. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Analysis, by End-user

        16.15. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Forecast, by End-user

            16.15.1. Pharmaceutical & Biotechnological Industry

            16.15.2. CROs

            16.15.3. CMOs

            16.15.4. Others

        16.16. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user

        16.17. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Value Share and Attractiveness Analysis, by Country/Sub-region

        16.18. Middle East and Africa Active Pharmaceutical Ingredients (API) Market Forecast, by Country/Sub-region

            16.18.1. GCC Countries

            16.18.2. South Africa

            16.18.3. Rest of Middle East & Africa

    17. Competition Landscape

        17.1. Competition Matrix

        17.2. Company Profiles

            17.2.1. Merck & Co., Inc.

                17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.1.2. Financial Overview

                17.2.1.3. Product Portfolio

                17.2.1.4. SWOT Analysis

                17.2.1.5. Strategic Overview

            17.2.2. Teva Pharmaceutical Industries Ltd.

                17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.2.2. Product Portfolio

                17.2.2.3. SWOT Analysis

                17.2.2.4. Strategic Overview

            17.2.3. Sanofi

                17.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.3.2. Product Portfolio

                17.2.3.3. SWOT Analysis

                17.2.3.4. Strategic Overview

            17.2.4. Pfizer

                17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.4.2. Product Portfolio

                17.2.4.3. SWOT Analysis

                17.2.4.4. Strategic Overview

            17.2.5. Novartis

                17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.5.2. Financial Overview

                17.2.5.3. Product Portfolio

                17.2.5.4. SWOT Analysis

                17.2.5.5. Strategic Overview

            17.2.6. Mylan

                17.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.6.2. Product Portfolio

                17.2.6.3. SWOT Analysis

                17.2.6.4. Strategic Overview

            17.2.7. Lonza

                17.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.7.2. Product Portfolio

                17.2.7.3. SWOT Analysis

                17.2.7.4. Strategic Overview

            17.2.8. WuXi AppTec Co., Ltd.

                17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.8.2. Product Portfolio

                17.2.8.3. SWOT Analysis

                17.2.8.4. Strategic Overview

            17.2.9. Piramal Pharma Solutions

                17.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.9.2. Product Portfolio

                17.2.9.3. SWOT Analysis

                17.2.9.4. Strategic Overview

            17.2.10. Hisun USA

                17.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.10.2. Product Portfolio

                17.2.10.3. SWOT Analysis

                17.2.10.4. Strategic Overview

            17.2.11. IPCA Laboratories Ltd

                17.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.11.2. Product Portfolio

                17.2.11.3. SWOT Analysis

                17.2.11.4. Strategic Overview

            17.2.12. AbbVie, Inc.

                17.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.12.2. Product Portfolio

                17.2.12.3. SWOT Analysis

                17.2.12.4. Strategic Overview

            17.2.13. Alembic Pharmaceuticals Limited

                17.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.13.2. Product Portfolio

                17.2.13.3. SWOT Analysis

                17.2.13.4. Strategic Overview

            17.2.14. BASF SE

                17.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.14.2. Product Portfolio

                17.2.14.3. SWOT Analysis

                17.2.14.4. Strategic Overview

            17.2.15. Biocon Ltd.

                17.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.15.2. Product Portfolio

                17.2.15.3. SWOT Analysis

                17.2.15.4. Strategic Overview

            17.2.16. Boehringer Ingelheim International GmbH

                17.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.16.2. Product Portfolio

                17.2.16.3. SWOT Analysis

                17.2.16.4. Strategic Overview

            17.2.17. Bristol-Myers Squibb Company

                17.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.17.2. Product Portfolio

                17.2.17.3. SWOT Analysis

                17.2.17.4. Strategic Overview

            17.2.18. Cambrex Corporation

                17.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.18.2. Product Portfolio

                17.2.18.3. SWOT Analysis

                17.2.18.4. Strategic Overview

            17.2.19. Dr. Reddy's Laboratories Ltd.

                17.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.19.2. Product Portfolio

                17.2.19.3. SWOT Analysis

                17.2.19.4. Strategic Overview

            17.2.20. Eli Lilly and Company

                17.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.20.2. Product Portfolio

                17.2.20.3. SWOT Analysis

                17.2.20.4. Strategic Overview

            17.2.21. GlaxoSmithKline plc

                17.2.21.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.2.21.2. Product Portfolio

                17.2.21.3. SWOT Analysis

                17.2.21.4. Strategic Overview

    List of Tables

    Table 01: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Manufacturer Type , 2017–2031

    Table 02: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Drug Type, 2017–2031

    Table 03: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2017–2031

    Table 04: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 05: Global Active Pharmaceutical Ingredients (API) Market Size (US$ Bn) Forecast, by End-user, 2017–2031

    Table 06: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Region, 2017–2031

    Table 07: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Country, 2017–2031

    Table 08: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Manufacturer Type, 2017–2031

    Table 09: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Drug Type, 2017–2031

    Table 10: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by API Type, 2017–2031

    Table 11: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Application, 2017–2031

    Table 12: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by End-user, 2017–2031

    Table 13: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Manufacturer Type, 2017–2031

    Table 15: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Drug Type, 2017–2031

    Table 16: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by API Type, 2017–2031

    Table 17: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Application, 2017–2031

    Table 18: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by End-user, 2017–2031

    Table 19: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Manufacturer Type, 2017–2031

    Table 21: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Drug Type, 2017–2031

    Table 22: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by API Type, 2017–2031

    Table 23: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Application, 2017–2031

    Table 24: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by End-user, 2017–2031

    Table 25: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 26: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Manufacturer Type, 2017–2031

    Table 27: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Drug Type, 2017–2031

    Table 28: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by API Type, 2017–2031

    Table 29: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Application, 2017–2031

    Table 30: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by End-user, 2017–2031

    Table 31: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 32: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Manufacturer Type, 2017–2031

    Table 33: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Drug Type, 2017–2031

    Table 34: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by API Type, 2017–2031

    Table 35: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by Application, 2017–2031

    Table 36: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Manufacturer Type (2020)

    Figure 03: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Drug Type, 2020

    Figure 04: Global Active Pharmaceutical Ingredients (API) Market Value Share, by API Type, 2020

    Figure 05: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Application, 2020

    Figure 06: Global Active Pharmaceutical Ingredients (API) Market Value Share, by End-user, 2020

    Figure 07: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Region, 2020

    Figure 08: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type, 2020 and 2031

    Figure 09: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by In-house Manufacturing, 2017–2031

    Figure 10: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Contract Manufacturing, 2017–2031

    Figure 11: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Manufacturer Type, 2021–2031

    Figure 12: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 13: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Branded or Innovative Prescription Drugs, 2017–2031

    Figure 14: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Generic Prescription Drugs, 2017–2031

    Figure 15: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Over-the-counter (OTC) Drugs, 2017–2031

    Figure 16: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Drug Type, 2021–2031

    Figure 17: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type, 2020 and 2031

    Figure 18: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Synthetic, 2017–2031

    Figure 19: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Biological, 2017–2031

    Figure 20: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Plant Extracts, 2017–2031

    Figure 21: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by API Type, 2021–2031

    Figure 22: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application, 2020 and 2031

    Figure 23: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Anti-infective, 2017–2031

    Figure 24: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Cardiovascular, 2017–2031

    Figure 25: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Neurological, 2017–2031

    Figure 26: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Metabolic Disorder, 2017–2031

    Figure 27: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Respiratory, 2017–2031

    Figure 28: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Oncology, 2017–2031

    Figure 29: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Others, 2017–2031

    Figure 30: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Application, 2021–2031

    Figure 31: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 32: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Pharmaceutical & Biotechnological Industry, 2017–2031

    Figure 33: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by CROs, 2017–2031

    Figure 34: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by CMOs, 2017–2031

    Figure 35: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn), by Others, 2017–2031

    Figure 36: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 37: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Region, 2020 and 2031

    Figure 38: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Region, 2021–2031

    Figure 39: North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 40: North America Active Pharmaceutical Ingredients (API) Market Value Share (%), by Country, 2020 and 2031

    Figure 41: North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2021–2031

    Figure 42: North America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type, 2019 and 2031

    Figure 43: North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Manufacturer Type, 2021–2031

    Figure 44: North America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 45: North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Drug Type, 2021–2031

    Figure 46: North America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type, 2020 and 2031

    Figure 47: North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by API Type, 2021–2031

    Figure 48: North America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application, 2020 and 2031

    Figure 49: North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Application, 2021–2031

    Figure 50: North America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 51: North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by End-user, 2021–2031

    Figure 52: Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 53: Europe Active Pharmaceutical Ingredients (API) Market Value Share (%), by Country, 2020 and 2031

    Figure 54: Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2021–2031

    Figure 55: Europe Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type, 2019 and 2031

    Figure 56: Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Manufacturer Type, 2021–2031

    Figure 57: Europe Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 58: Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Drug Type, 2021–2031

    Figure 59: Europe Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type, 2020 and 2031

    Figure 60: Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by API Type, 2021–2031

    Figure 61: Europe Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application, 2020 and 2031

    Figure 62: Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Application, 2021–2031

    Figure 63: Europe Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 64: Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by End-user, 2021–2031

    Figure 65: Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 66: Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share (%), by Country, 2020 and 2031

    Figure 67: Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2021–2031

    Figure 68: Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type, 2019 and 2031

    Figure 69: Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Manufacturer Type, 2021–2031

    Figure 70: Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 71: Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Drug Type, 2021–2031

    Figure 72: Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type, 2020 and 2031

    Figure 73: Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by API Type, 2021–2031

    Figure 74: Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application, 2020 and 2031

    Figure 75: Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Application, 2021–2031

    Figure 76: Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 77: Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by End-user, 2021–2031

    Figure 78: Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 79: Latin America Active Pharmaceutical Ingredients (API) Market Value Share (%), by Country, 2020 and 2031

    Figure 80: Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2021–2031

    Figure 81: Latin America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type, 2019 and 2031

    Figure 82: Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Manufacturer Type, 2021–2031

    Figure 83: Latin America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 84: Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Drug Type, 2021–2031

    Figure 85: Latin America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type, 2020 and 2031

    Figure 86: Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by API Type, 2021–2031

    Figure 87: Latin America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application, 2020 and 2031

    Figure 88: Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Application, 2021–2031

    Figure 89: Latin America Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 90: Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by End-user, 2021–2031

    Figure 91: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 92: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share (%), by Country, 2020 and 2031

    Figure 93: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2021–2031

    Figure 94: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Manufacturer Type, 2019 and 2031

    Figure 95: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Manufacturer Type, 2021–2031

    Figure 96: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Drug Type, 2020 and 2031

    Figure 97: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Drug Type, 2021–2031

    Figure 98: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by API Type, 2020 and 2031

    Figure 99: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by API Type, 2021–2031

    Figure 100: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Application, 2020 and 2031

    Figure 101: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Application, 2021–2031

    Figure 102: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 103: Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by End-user, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved

Active Pharmaceutical Ingredients (API) Market Report, 2021-2031

Schedule a Call